SEARCH:   Advanced

Blood, 1 January 2006, Vol. 107, No. 1, pp. 190-196. Prepublished online as a Blood First Edition Paper on September 8, 2005; DOI 10.1182/blood-2005-03-1024. This Article Full Text (PDF) All Versions of this Article: 2005-03-1024v1 107/1/190    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Camilleri-Broet, S. Articles by Martin, A. Search for Related Content PubMed PubMed Citation Articles by Camilleri-Broet, S. Articles by Martin, A. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 14, 2005 Accepted July 20, 2005 A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: Analysis of 83 cases Sophie Camilleri-Broet*, Emmanuelle Criniere, Philippe Broet, Vincent Delwail, Karima Mokhtari, Anne Moreau, Michele Kujas, Martine Raphael, Wafae Iraqi, Catherine Sautes-Fridman, Philippe Colombat, Khe Hoang-Xuan, and Antoine Martin Universite Paris-Descartes, Faculte de medecine; Hotel Dieu, AP-HP, Paris, France; GOELAMS (Groupe Ouest Est des Leucemies et Autres Maladies du Sang), Paris, France; INSERM U255, Centre de Recherches Biomedical des Cordeliers, Paris, France INSERM U711, Universite P. et M. Curie Paris VI, Groupe Hospitalier Pitie-Salpetriere, Paris, France Faculte de Medecine Paris-Sud, Service de Sante Publique, AP-HP, Villejuif, France GOELAMS (Groupe Ouest Est des Leucemies et Autres Maladies du Sang), Paris, France; Oncologie Hematologique et Therapie Cellulaire, Hopital Bernard, Poitiers, France INSERM U711, Universite P. et M. Curie Paris VI, Groupe Hospitalier Pitie-Salpetriere, Paris, France; Laboratoire de Neuropathologie R. Escourolle, Groupe Hospitalier Pitie Salpetriere, AP-HP, Paris, France GOELAMS (Groupe Ouest Est des Leucemies et Autres Maladies du Sang), Paris, France; Anatomie Pathologique, Hotel Dieu, Nantes, France GOELAMS (Groupe Ouest Est des Leucemies et Autres Maladies du Sang), Paris, France; Service d'Hematologie et Immunologie Biologiques, Cytogenetique, INSERM E109, CHU Bicetre, Universite Paris-Sud 11, Le Kremlin Bicetre, France Service de Neurologie Mazarin, Groupe Hospitalier Pitie-Salpetriere, AP-HP, Paris, France INSERM U255, Centre de Recherches Biomedical des Cordeliers, Paris, France GOELAMS (Groupe Ouest Est des Leucemies et Autres Maladies du Sang), Paris, France; Hematologie, Hopital Bretonneau, Tours, France INSERM U711, Universite P. et M. Curie Paris VI, Groupe Hospitalier Pitie-Salpetriere, Paris, France; Service de Neurologie Mazarin, Groupe Hospitalier Pitie-Salpetriere, AP-HP, Paris, France GOELAMS (Groupe Ouest Est des Leucemies et Autres Maladies du Sang), Paris, France; Faculte de medecine Paris XIII, Anatomie Pathologique, Hopital Avicenne, AP-HP, Bobigny, France * Corresponding author; email: sophie.camilleri-broet{at}htd.ap-hop-paris.fr. Most primary central nervous system lymphomas (PCNSL) in immunocompetent patients are diffuse large B-cell lymphomas (DLBCL) characterized by poor prognosis, compared to systemic forms. A germinal center B-cell like (GCB) origin of PCNSL was hypothesized based on BCL-6 expression and ongoing mutational activity. Our goal herein was to determine, for 83 PCNSL, the percentages of GCB and activated B-cell like (ABC) phenotypes and their prognostic significance. CD10, BCL-6, MUM1, BCL-2 and CD138 antigens were immunohistochemically labeled on paraffin-embedded sections; the first 4 were positive in 2.4%, 55.5%, 92.6% and 55.5% of the tumors, respectively. None of the 56 tested samples expressed CD138. Among the 82 patients with complete information, 79 (96.3%) were classified as ABC; 42 (51.2%) expressed BCL-6+MUM1+, suggesting an "activated GCB" origin, 33 (40.2%) were exclusively MUM1+ and the remaining 4 (4.9%) were negative for all markers tested. These findings provide new insights into interpreting the poor PCNSL prognostic, which may, in part, be due to biological aggressiveness associated with its activated B-cell like pattern. We postulate assigning PCNSL a histogenetic "time-slot", overlapping late GC and early post-GC, that could explain the predominant ABC phenotype observed. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan Primary CNS Lymphoma in Immunocompetent Patients Oncologist, May 1, 2009; 14(5): 526 - 539. [Abstract] [Full Text] [PDF] C. Kadoch, E. B. Dinca, R. Voicu, L. Chen, D. Nguyen, S. Parikh, J. Karrim, M. A. Shuman, C. A. Lowell, P. A. Treseler, et al. Pathologic Correlates of Primary Central Nervous System Lymphoma Defined in an Orthotopic Xenograft Model Clin. Cancer Res., March 15, 2009; 15(6): 1989 - 1997. [Abstract] [Full Text] [PDF] M. Montesinos-Rongen, R. Siebert, and M. Deckert Primary lymphoma of the central nervous system: just DLBCL or not? Blood, January 1, 2009; 113(1): 7 - 10. [Full Text] [PDF] R. Hassan, C. G. Stefanoff, F. Felisbino, M. H. M. Barros, I. R. Zalcberg, C. E. Klumb, R. S. Bigni, and H. N. Seuanez Second Epstein-Barr Virus-Associated Burkitt's Lymphoma of the CNS in a Child With Progressive Renal Failure J. Clin. Oncol., June 20, 2008; 26(18): 3085 - 3087. [Full Text] [PDF] H. W. Tun, D. Personett, K. A. Baskerville, D. M. Menke, K. A. Jaeckle, P. Kreinest, B. Edenfield, A. C. Zubair, B. P. O'Neill, W. R. Lai, et al. Pathway analysis of primary central nervous system lymphoma Blood, March 15, 2008; 111(6): 3200 - 3210. [Abstract] [Full Text] [PDF] J. O. Armitage How I treat patients with diffuse large B-cell lymphoma Blood, July 1, 2007; 110(1): 29 - 36. [Full Text] [PDF] M. Booman, J. Douwes, M.-C. Legdeur, J. van Baarlen, E. Schuuring, and P. Kluin From brain to testis: immune escape and clonal selection in a B cell lymphoma with selective out-growth in two immune sanctuariesy Haematologica, June 1, 2007; 92(6): e69 - e71. [Abstract] [Full Text] [PDF] I. Oschlies, W. Klapper, M. Zimmermann, M. Krams, H.-H. Wacker, B. Burkhardt, L. Harder, R. Siebert, A. Reiter, and R. Parwaresch Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster) Multicenter Trial Blood, May 15, 2006; 107(10): 4047 - 4052. [Abstract] [Full Text] [PDF] J. L. Rubenstein, J. Fridlyand, A. Shen, K. Aldape, D. Ginzinger, T. Batchelor, P. Treseler, M. Berger, M. McDermott, M. Prados, et al. Gene expression and angiotropism in primary CNS lymphoma Blood, May 1, 2006; 107(9): 3716 - 3723. [Abstract] [Full Text] [PDF] L. M. DeAngelis and F. M. Iwamoto An Update on Therapy of Primary Central Nervous System Lymphoma Hematology, January 1, 2006; 2006(1): 311 - 316. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020